Clinical trial
Aflibercept for Relapsed Multiple Myeloma
NCT00437034 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00437034 |
|---|---|
| Title | Aflibercept for Relapsed Multiple Myeloma |
| Official title | A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage II Multiple Myeloma, Stage III Multiple Myeloma |
| Intervention type | Biological |
| Interventions | aflibercept |
| Enrollment | 6 |
| Start date | Jan 1, 2007 |
| Primary completion | Oct 1, 2010 |
| Completion | Apr 1, 2011 |
| First posted | Feb 19, 2007 |
| Last update posted | Feb 8, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: